Who
Kevin G. Shaw
Sr VP, General Counsel
Company insider
Files Form 4 as: Sr VP, General Counsel, NextCure.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Feb 2023
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,270 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,270 at $0.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,125 at $0.00 | filing |
| 29 Mar 2024filed 2 Apr 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,900 at $0.00 | filing |
| 31 Jan 2024filed 1 Feb 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,125 at $0.00 | filing |
| 28 Feb 2023filed 1 Mar 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.